Prakt. lékáren. 2009; 5(5): 229-232

Swine (Mexican) H1N1 flu - epidemiology, diagnostic, therapy

doc. MUDr. Jiří NečaS, CSc1, MUDr. PharmDr. Lenak Bartošíková, Ph.D1, MUDr. Vít Perlík1, MUDr. Tomáš Bartošík, Ph.D2, MUDr. Petr Fráňa, Ph.D3
1 Ústav fyziologie Lékařské fakulty Univerzity Palackého v Olomouci
2 Anesteziologicko-resuscitační klinika LF MU a FN u sv. Anny v Brně
3 II. interní klinika FN u sv. Anny LF MU, Brno

Influenza A virus is well known for its capability for genetic changes either through antigen drift or antigen shift. In the 20th century

alone, there were three overwhelming pandemics, in 1918, 1957 and 1968, caused by H1N1 (Spanish flu), H2N2 (Asian flu) and H3N2

(Hong Kong flu), respectively. Since March 2009, the outbreak of a new strain of influenza A (H1N1) virus infection in humans has raised

increasing concerns of the risk of a global flu epidemic. The new influenza A (H1N1) viruses are currently susceptible to the neuraminidase

inhibitors (NAIs) oseltamivir and zanamivir but resistant to amantadine or rimantadine (adamantane or M2 inhibitor drugs). Oseltamivir

is administered orally and gives higher systemic level. Zanamivir is delivered by oral inhalation with low systemic absorption.

Keywords: swine flu, virus A (H1N1), oseltamivir, zanamivir.

Published: August 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
NečaS J, Bartošíková L, Perlík V, Bartošík T, Fráňa P. Swine (Mexican) H1N1 flu - epidemiology, diagnostic, therapy. Praktické lékárenství. 2009;5(5):229-232.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hsieh YC, Wu TZ, Liu DP, et al. Influenza Pandemics: Past, Present and Future. Review article. J Formos Med Assoc 2006; 105(1): 1-6. Go to original source... Go to PubMed...
    2. Melicharová M. Molekulová podstata chřipkových virů. Bakalářská práce. Brno 2006.
    3. Taubenberger JK, Morens DM, Fauci AS. The Next Influenza Pandemic. Can It Be Predicted? JAMA 2007; 297(18): 2025-2027. Go to original source... Go to PubMed...
    4. Kilbourne ED. Influenza Pandemics of the 20th Century. Emerg Infect Diseases 2006; 12(1): 9-14. Go to original source... Go to PubMed...
    5. http://special.novinky.cz/chripka/sezonni/pandemiechripky.html
    6. Beigel JH, Farrar J, Han AM, et al. (The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5). Avian Influenza A (H5N1) Infection in Humans. N Engl J Med 2005; 353: 1374-1385. Go to original source... Go to PubMed...
    7. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A: Hong Kong: 156:97 (H5N1) and A: Hong Kong: 1074:99 (H9N2) influenza viruses. Antivir Res 2000; 48: 101-115. Go to original source... Go to PubMed...
    8. http://www.who.int/crs/don/2009_08_28/eu/index.html.
    9. www.mzcr.cz
    10. Tkadlecová H. Novel flu A (H1N1). Aktualizace ke dni 3. 6. 2009. Protiepidemický odbor KHS ZK se sídlem ve Zlíně.
    11. Davis W. Swine Influenza (H1N1): Updated Recommendations for Testing and Treatment. 2009: 1-4.
    12. Macešková B, Fridrichová D. Monitorování terapie astmatických pacientů v lékárně. Klin farmakol farm 2005; 19(4): 206-210.
    13. WHO: Clinical management of human infection with new influenza A (H1N1) virus: initial Guyance. 2009: 1-6.
    14. IzumiY, Tokuda K, O'Dell K, Zorumski CHF, Narahashi T. Synaptic and Behavioral Interactions of Oseltamivir (Tamiflu) with Neurostimulants. Hum Exp Toxicol 2008; 27(12): 911-917. Go to original source... Go to PubMed...
    15. Product Information. Tamiflu capsules, Roche, August 2008: 1-23.
    16. Product Information. Tamiflu capsules, Roche, December 2005: 1-18.
    17. Rungrotmongkol T, Intharathep P, Malaisree M, et al. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. Biochem Biophys Res Commun 2009; 385(3): 390-394. Go to original source... Go to PubMed...
    18. Kvasničková A. Shikimová kyselina k výrobě přípravku proti ptačí chřipce. 8. 1. 2006. http://www.agronavigator.cz/default.asp?ids=127&ch=1&typ=1&val=42250.
    19. Snell P, Oo C, Dorr A, Barrett J. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. Br J Clin Pharmacol 2002; 54: 372-377. Go to original source... Go to PubMed...
    20. Annex I. Tamiflu. Summary of product characteristics.
    21. Höffken G, Gillissen A. Efficacy and safety of zanamivir in patients with influenza - impal of age, severity of infections and specific risk factors. Med Microbiol Immunol 2002; 191: 169-173. Go to original source... Go to PubMed...
    22. Product Information. Relenza(R), Zanamivir for inhalation. Glaxo Wellcome Inc. Research Triangle Park, 1999: 1-9.
    23. Vícha R, Potáček M. Kde roste adamantan. Chem Listy 2004; 98: 68-74.
    24. Vicente D, Cilla G, Montes M, Mendiola J, Pérez-Trallero E. Rapid spread of drug-resistant influenza A viruses in the Basque Country, northern Spain, 2000-1 to 2008-9. Eurosurveillance 2009; 14(20): 1-3. Go to original source... Go to PubMed...
    25. SPC. MARIDIN 100. PLIVA - Lachema a.s., 2005: 1-5.
    26. Hayden FG, Lobo M, Husary EK, Eason CU. Efficacy of intranasal GG167 in experimental human influenza A and B virus infection. Options for the control of influenza III, International congress series, 1996; 1123: 718-725. Go to original source...
    27. Petráš M. Účinnost chřipkových vakcín. Praktické lékárenství 2007; 3(6): 275-279.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.